Sportmesh(TM) Tissue Reinforcement, made of Artelon(R),
is launched globally by Arthrotek, a Biomet company, at the AAOS
meeting in Chicago this week.
Sportmesh(TM) is a patch designed to be used in surgery to strengthen the repair of injured rotator cuff in the shoulder. Causes of the injury may include every day activities such as lifting or reaching. The injury is also common among active people and people with physically demanding jobs. More than 300,000 surgical procedures are performed annually in the United States only.
Sportmesh(TM) is the first synthetic patch to the market for this indication. The most commonly used materials today are based on collagen derived from animals such as porcine and bovine.
Sportmesh(TM) is Artimplant's second product after the Artelon(R) Spacer CMC-I for thumb base osteoarthritis to be marketed in the United States. The product is licensed to Biomet and is expected to increase Artimplant's revenues.
"Sportmesh(TM) will considerably increase our presence on the market, and will be important for the positioning of Artelon(R) as a biomaterial," says Artimplant CEO Tord Lendau.
Artelon(R) - a unique biomaterial
Sportmesh(TM) is made of Artelon(R), a unique long-term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility in hard and soft tissue - Artelon(R) offers new solutions to unmet clinical needs in several therapy areas.
About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.
About Biomet
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. The Company's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This information was brought to you by Waymaker http://www.waymaker.net
Sportmesh(TM) is a patch designed to be used in surgery to strengthen the repair of injured rotator cuff in the shoulder. Causes of the injury may include every day activities such as lifting or reaching. The injury is also common among active people and people with physically demanding jobs. More than 300,000 surgical procedures are performed annually in the United States only.
Sportmesh(TM) is the first synthetic patch to the market for this indication. The most commonly used materials today are based on collagen derived from animals such as porcine and bovine.
Sportmesh(TM) is Artimplant's second product after the Artelon(R) Spacer CMC-I for thumb base osteoarthritis to be marketed in the United States. The product is licensed to Biomet and is expected to increase Artimplant's revenues.
"Sportmesh(TM) will considerably increase our presence on the market, and will be important for the positioning of Artelon(R) as a biomaterial," says Artimplant CEO Tord Lendau.
Artelon(R) - a unique biomaterial
Sportmesh(TM) is made of Artelon(R), a unique long-term degradable biomaterial that acts as a temporary scaffold to facilitate formation of new host tissue. Due to its versatility and unique combination of properties - long-term degradation, mechanical properties similar to human tendons and excellent biocompatibility in hard and soft tissue - Artelon(R) offers new solutions to unmet clinical needs in several therapy areas.
About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.
About Biomet
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. The Company's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This information was brought to you by Waymaker http://www.waymaker.net
© 2006 Business Wire
